Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001725160-25-000105
Filing Date
2025-05-14
Accepted
2025-05-14 16:13:06
Documents
76
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q zntl-20250331.htm   iXBRL 10-Q 1366183
2 EX-31.1 zentalis10-qq12025ex311.htm EX-31.1 10855
3 EX-31.2 zentalis10-qq12025ex312.htm EX-31.2 11110
4 EX-32.1 zentalis10-qq12025ex321.htm EX-32.1 5634
5 EX-32.2 zentalis10-qq12025ex322.htm EX-32.2 5495
11 zntl-20250331_g1.jpg GRAPHIC 95675
  Complete submission text file 0001725160-25-000105.txt   6816342

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20250331.xsd EX-101.SCH 41059
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT zntl-20250331_cal.xml EX-101.CAL 78126
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20250331_def.xml EX-101.DEF 189198
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20250331_lab.xml EX-101.LAB 573210
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20250331_pre.xml EX-101.PRE 404201
79 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20250331_htm.xml XML 782714
Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

EIN.: 823607803 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39263 | Film No.: 25945644
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)